多原发非小细胞肺癌诊断治疗及预后的系统性综述-解放军医学院学报.PDFVIP

解放军医学院学报 Acad J Chin PLA Med Sch Aug 2016，37（8） 901 多原发非小细胞肺癌诊断、治疗及预后的系统性综述 刘　毅，初向阳 解放军总医院 胸外科，北京　100853 摘要 ：近年来，由于诊断和检查手段的改进及人口老龄化加剧，多原发肺癌 (multiple primary lung cancer，MPLC) 的发病率 在世界范围内呈持续性增长趋势。MPLC 包括同时性多原发肺癌 (synchronous multiple primary lung cancers，sMPLC) 及异时 性多原发肺癌 (metachronous multiple primary lung cancers，mMPLC)。非小细胞肺癌 (non-small cell lung cancer，NSCLC) 中， 有 0.2% ~ 8% 为 MPLC。MPLC 与肺内转移癌 (intrapulmonary metastases，IM) 的鉴别比较困难，主要通过病理结果分析进行 鉴别。基因检测可在一定程度上鉴别 IM 和 MPLC。手术切除和立体定性放疗被认为是治疗 MPLC 的有效方法。MPLC 的预 后优于 IM，其生存期由最高分期的肿瘤决定。 关键词 ：同时性多原发肺癌 ；异时性多原发肺癌 ；诊断 ；治疗 ；预后 中图分类号 ：R 734.2　文献标志码 ：A　文章编号 ：2095-5227(2016)08-0901-05　DOI ：10.3969/j.issn.2095-5227.2016.08.022 网络出版时间：2016-05-05 10:33　　　 网络出版地址 ：/kcms/detail/11.3275.R1033.004.html Diagnosis, treatment and prognosis of patients with multiple primary non-small cell lung cancer: A systematic review LIU Yi, CHU Xiangyang Department of Thoracic Surgery, Chinese PLA General Hospital, Beij ing 100853, China Corresponding author: CHU Xiangyang. Email: drchu30 1@ Abstract: The incidence of multiple primary lung cancers (MPLC), including synchronous multiple primary lung cancers (sMPLC) and metachronous multiple primary lung cancers (mMPLC), has been increasing in recent years due to the development of screenning, early detection techniques and the ageing population. A substantial percentage (0.2%-8%) of all newly diagnosed non- small cell lung cancer (NSCLC) cases are MPLCs. The distinction between multiple primary lung cancers and intrapulmonary metastases (IM) is based on pathological criteria, however, it is very difficult. Newly developed genetic methods are believed to be helpful for the distinction between MPLC and IM. Surgical treatment and stereotactic body radiation therapy are considered as effective methods in treating MPLC. Surgery options are varies from person to person due to different conditions of each patient. The prognosis of patie